FDA Approved: AFINITOR — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for Afinitor (everolimus) from Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer Hr-positive
• Pancreatic Neuroendocrine Tumor
• Renal Cell Carcinoma
• Subependymal Giant Cell Astrocytoma
• Tuberous Sclerosis Complex-associated Renal Angiomyolipoma

Drugs mentioned

• Afinitor (everolimus)

Snippet

SUPPL AP for AFINITOR (EVEROLIMUS)